Advertisement
Canada markets open in 2 hours 57 minutes

  • S&P/TSX

    21,871.96
    +64.59 (+0.30%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CAD/USD

    0.7295
    -0.0006 (-0.08%)
     

  • CRUDE OIL

    81.78
    -0.12 (-0.15%)
     

  • Bitcoin CAD

    90,692.00
    +185.90 (+0.21%)
     

  • CMC Crypto 200

    1,421.52
    +6.76 (+0.48%)
     

  • GOLD FUTURES

    2,313.70
    -32.70 (-1.39%)
     

  • RUSSELL 2000

    1,967.47
    +19.82 (+1.02%)
     

  • 10-Yr Bond

    4.6230
    +0.0080 (+0.17%)
     

  • NASDAQ futures

    17,399.25
    +49.25 (+0.28%)
     

  • VOLATILITY

    16.68
    -0.26 (-1.53%)
     

  • FTSE

    8,063.71
    +39.84 (+0.50%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6842
    -0.0008 (-0.12%)
     

What You Should Know about Nektar’s Cash Flows and Valuations

Kenneth Smith
Updated
What You Should Know about Nektar’s Cash Flows and Valuations

Nektar Therapeutics (NKTR) used up $52.5 million on operating activities in Q1 2018 compared with $34.6 million in Q1 2017. Operating cash flow in Q1 2018 included $57.5 million of net operating cash use along with $5 million for interest payments on Nektar’s senior secured notes partially offset by the receipt of a milestone payment of $10 million from Baxalta. Nektar expects cash used in operating activities in fiscal 2018 to increase as compared with fiscal 2017 mainly as a result of higher research and development expenses.

Continue reading